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Background: The aim of the present study was to assess the influence of antibiotic therapy on fat assimilation in cystic fibrosis (CF) patients with
small intestine bacterial overgrowth (SIBO).
Materials and methods: Twenty six pancreatic insufficient CF patients with bronchopulmonary exacerbation and diagnosed SIBO (positive
hydrogen–methane breath test) entered the study. 13C mixed triglyceride breath test was performed before and after antibiotic therapy. Sixteen
subjects were treated intravenously (ceftazidime and amikacin), ten patients orally (ciprofloxacin).
Results: Cumulative percentage dose recovery changed significantly in the subgroup receiving antibiotics orally [median (mean±SEM): 3.6%
(4.5±1.3%) vs. 7.2 (6.9±1.6%); p=0.019]. In the subgroup with intravenous drug administration, the tendency towards improvement was noted
[2.7 (4.3±1.5%) vs. 5.2 (5.7±0.8%); p=0.109].
Conclusions: Antibiotic therapy applied in CF patients with SIBO in the course of pulmonary exacerbation results in a significant improvement of
fat digestion and absorption.
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Small intestine bacterial overgrowth (SIBO) may frequently
occur in subjects with cystic fibrosis (CF) [1,2]. Its typical
symptoms comprise abdominal discomfort, bloatening, flatu-
lence, gasses and appear from several minutes to hours after
meal [2,3]. Due to their similarity to typical gastrointestinal
manifestation in CF, SIBO may remain undiagnosed unless
specifically assessed. It is suggested that due to SIBO, thed by Elsevier B.V. All rights reserved.
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result in mucosal damage and interfere with digestion and
absorption [4,5]. Therefore, the presence of SIBO in CF
subjects may potentially aggravate malabsorption.
Intensive inflammation of the CF mouse small intestine was
reported [6]. Results obtained in a subsequent study suggested,
that bacterial overgrowth plays an important role in inflamma-
tion and contributes to the failure in thrive in this model of CF
[7]. We have recently compared the effectiveness of fat
absorption in CF patients with and without SIBO. No
significant differences were observed [8]. In a following study
we have also failed to document the effect of antibiotic therapy
applied in non-selected cystic fibrosis (CF) patients in the
course of pulmonary exacerbation on intestinal digestion and
absorption as measured by 13C-labeled mixed triglyceride
breath test (13C MTG-BT). Although observed changes of
cumulative percentage dose recovery (CPDR) in the whole
studied group were not significant, the tendency towards the
improvement (pb0.100) was observed [8]. Therefore, we aimed
to assess the influence of antibiotic therapy on fat assimilation
in CF patients with SIBO.
2. Materials and methods
The study comprised 26 CF patients (15 females and 11
males) (Table 1). Diagnosis of CF was based on history, clinical
manifestation and increased sweat chloride concentrations and
in the majority of patients confirmed by the CFTR gene
analysis. The genotypes of the studied patients were as follow:
F508del/F508del (n=12), F508del/CFTRdel2,3(21kB) (n=2),
F508del/R553X (n=1), CFTRdel2,3(21kB)/CFTRdel2,3(21kB)
(n=2), F508del/2143delT (n=1), F508del/2183AA-G (n=1),
F508del/W1282X (n=1), 1717-1G-A/N1303K (n=1), F508del/
unknown mutation (n=4), and unknown mutation/unknown
mutation (n=1).
Inclusion criteria comprised the willingness to participate in
the study, exocrine pancreatic insufficiency (fecal elastase-1
concentration b100 μg/g and the presence of steatorrhea),
pulmonary exacerbation (demanding antibiotic therapy) and the
presence of SIBO (based upon results of HMBT) [9,10].
Exclusion criteria comprised: antibiotic therapy (i.v. or p.os) six
weeks prior to the test, liver cirrhosis, diabetes mellitus, oxygen
dependency, the use of systemic corticosteroids, severe
pulmonary exacerbation or any pulmonary complication.
Glucose HMBT was performed after overnight fast. Patients
were instructed not to eat or drink for at least 12 h before the testTable 1
Basic epidemiological and clinical data of cystic fibrosis patients (n=26).
Parameter Range Median (mean±SEM)
Age (years) 12–32 19 (20.8±1.0)
Body weight (Z-score) −2.42–0.78 −0.73 (−0.70±0.16)
FEV1 (%) 54.4–112.4 81.2 (81.9±2.6)
Fecal elastase-1 (μg/g) BDL*–88 6 (10±4)
AlAT (U/l) 8–52 23 (22.6±2.0)
GGTP (U/l) 6–64 16 (18.4±2.6)
*BDL— below detection limit.and to avoid slowly digesting foods like beans and similar
vegetables, brans or high-fiber cereals the day before the test.
Patients were not allowed to smoke, sleep or exercise
vigorously for at last 1 h before or at any time during the test.
Every patient received glucose dissolved in water orally in a
dose of 1.5 g/kg up to maximum 75 g. Breath samples were
collected at baseline (fasting) and at 15, 30, 45, 60, 90, and
120 min after glucose ingestion. Samples were analyzed with
QuinTron MicroLyser DP Plus (Quintron, USA). A positive
HMBT was defined as a rise of ≥20 ppm hydrogen or
≥12 ppm methane over baseline during the test.
In all enrolled CF subjects, 13C MTG-BT was performed to
assess lipid digestion and absorption, before and after antibiotic
therapy. Sixteen patientswere treated intravenouslywith amikacin
and ceftazidime, in respective doses: 20–35 mg/kg/24 h and 150–
250 mg/kg/24 h, remaining 10 subjects were given ciprofloxacin
in a dose of 35–50 mg/kg/24 h (in latter two in proper divided
doses) according to existing CF standards. The assignment of
patients to treatment groups was based upon psychological and
social aspects (patients' abilities and wills). Patients did not differ
in terms of their clinical status. The assignment of patients to
treatment groups was based on sputum culture with bacterial
sensitivity tests and psychological/social aspects (i.e. willingness/
permission for hospitalization). Patients did not differ significantly
in terms of the nature of pulmonary exacerbations.
13C MTG-BT was performed after overnight fast. Each of
the studied subjects received 150 mg 13C mixed triglyceride
with 0.25 g butter per kg body weight mixed on a slice of bread.
Breath samples were collected at baseline (fasting) and at 30,
60, 90, 120, 150, 180, 210, 240, 270, 300, 330, and 360 min
after test meal ingestion. The samples were analyzed with IRIS
13C-Analyser System (Wagner, Bremen, Germany). CPDR was
considered to reflect digestion and absorption of lipids. In
healthy non-CF individuals it should be higher than 14.5%.
Values are expressed as ranges, means (±SEM) and
medians. The differences in CPDR before and after antibiotic
therapy were determined with the use of Wilcoxon-rank test.
The effectiveness of antibiotic therapy in curing SIBO was
assessed using Fisher test. The level of significance was set at
pb0.05.
The protocol of the investigation was approved by Ethical
Committee of Poznań University of Medical Sciences, Poland.3. Results
Antibiotic therapy resulted in a significant reduction of
hydrogen/methane production in both treated groups (pb0.005
and pb0.0015 for oral and intravenous therapy, respectively) as
shown in Fig. 1A–B. The cure of SIBO was achieved
respectively in 9 (90%) and 7 (43.8%) patients treated orally
and intravenously, being more effective in the latter group
(pb0.037). The results of 13C MTG-BT have been presented in
Table 2. The values of CPDR changed significantly in the
subgroup receiving antibiotics orally (pb0.019). In the
subgroup receiving intravenously the tendency towards the
improvement (pb0.109) was observed.
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Fig. 1. A. Changes in mean values of hydrogen/methane expiration in CF
patients receiving antibiotics orally. *The sum of hydrogen and doubled
methane expiration has been given. B. Changes in mean values of hydrogen/
methane expiration in CF patients receiving antibiotics intravenously. *The sum
of hydrogen and doubled methane expiration has been given.
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We documented in the present study the positive influence of
antibiotic therapy on fat assimilation in CF patients with SIBO.
According to literature search it is the first study assessing such
a relationship in a reliable way in humans.
Reilly et al. attempted to assess the effect of an acute
bronchopulmonary exacerbation on energy balance in a groupTable 2
Lipid digestion and absorption in cystic fibrosis patients with small intestine
bacterial overgrowth undergoing antibiotic therapy based upon cumulative 13C
dose recovery (CDPR).
Studied group (n) CPDR (%) Statistical
significance
Parameter Before After
CF-IV ⁎⁎ (16) Median 2.7 5.2 0.109
Mean±SEM 4.3±1.5 5.7±0.8
Range BDL ⁎–20.2 1.8–11.4
CF-PO ⁎⁎⁎ (10) Median 3.6 7.2 0.019
Mean±SEM 4.5±1.3 6.9±1.6
Range BDL ⁎–9.2 0.8–12.8
⁎ BDL— below detection limit.
⁎⁎ CF-IV— subjects receiving antibiotics intravenously.
⁎⁎⁎ CF-PO— subjects receiving antibiotics orally.of 14 CF children [11]. Since the relationship between timing of
food intake and stool collection as well as between stable period
and exacerbation was not clear, the obtained results raise some
doubts. The data on the effectiveness of fat digestion and
absorption as measured by the coefficient of fat absorption
(CFA) were available in 10 out of 14 studied subjects. CFA
improved during exacerbation in 7 subjects and worsened in 1
patient. However, no significant effect was observed. We have
conducted a similar study assessing the influence of antibiotic
therapy on fat assimilation with the use of reliable stable isotope
breath test. The strict criteria of timing were used, the test was
conducted directly before and after antibiotic therapy.
Norkina et al. proved that intestinal bacterial overgrowth is
related to intestinal inflammation and failure in thrive in the CF
mouse model [6]. Significant CF mice weight gain at the end of
a 3-weeks antibiotic treatment (ciprofloxacin and metronida-
zole) was observed. Having in mind this effect we aimed
previously to assess the significance of SIBO for CF human
lipid assimilation. We did not observe any differences between
subjects with and without SIBO [8]. In a subsequent study,
antibiotic therapy applied in non-selected CF patients resulted
in the tendency towards the improvement of CPDR (pb0.100).
However, the effects observed in subgroups receiving antibi-
otics either orally or intravenously were less evident (pb0.167
and pb0.327, respectively). Therefore, we planned in the
present study to determine fecal fat assimilation before and after
antibiotic treatment exclusively in CF patients with documented
SIBO [12]. Considering limited sensitivity and specificity of
breath test for the detection of SIBO, we used very strict criteria
including exclusively patients with a significant increase of
hydrogen and or methane exhalation after glucose loading. We
documented in the present study significant changes of CPDR
due to oral antibiotic therapy with ciprofloxacin. Although
significant improvement of fat digestion and absorption as
measured by 13C MTG-BT was observed, the effects of
antibiotic therapy were minor. The relationship documented in
animal model does not seem to be so clear in humans [7].
Clinical significance of SIBO for lipid digestion and absorption
in CF patients demands further studies.
In conclusion, oral antibiotic therapy applied in CF patients
with small intestine bacterial overgrowth in the course of
pulmonary exacerbation results in statistically significant
improvement of fat digestion and absorption.
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